Inmedix
Seattle
About Inmedix
Inmedix has discovered and is commercializing a novel class of diagnostics and therapeutics. Their approach focuses on autonomic nervous system (ANS) control of stress responses within the brain. In the setting of an autoimmune disease, ANS stress can significantly intensify an autoimmune disease. They call it Immuno-autonomics. They seek to understand and block this process to allow current autoimmune disease therapies to work much better.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Last round: Series Unknown (Nov 2024)
- Website: inmedix.com
- Phone: 206-412-5347
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/inmedix-44576 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.